SCHEMBL20135913

SCHEMBL20135913

Cc1ccc(-c2ncco2)c(C=O)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.38
ADORA2A P29274 2/20 0.38
HCRTR2 O43614 8/20 0.35
HCRTR1 O43613 7/20 0.35
S100A4 P26447 1/20 0.34
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
RECQL P46063 1/20 0.33
PIN1 Q13526 1/20 0.33
TP53 P04637 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
ADORA1 P30542 2/20 0.31
TLR7 Q9NYK1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2488705 0.75 HCRTR1 (0.41) HCRTR2HCRTR1S100A4
SCHEMBL16031447 0.75 HCRTR2 (0.44) BRD4ADORA2AHCRTR2HCRTR1PIN1
SCHEMBL29912137 0.73 S100A4 (0.38) BRD4HCRTR2HCRTR1S100A4NPC1
SCHEMBL9955665 0.73 S100A4 (0.38) BRD4HCRTR2HCRTR1S100A4NPC1
SCHEMBL2495796 0.73 PDE4B (0.38) S100A4
SCHEMBL607939 0.73 OPRK1 (0.43) HCRTR2HCRTR1S100A4NPC1RAB9A
SCHEMBL20135908 0.72 OPRK1 (0.37) BRD4HCRTR2HCRTR1PIN1HPGDS
SCHEMBL16030471 0.72 CFTR (0.45) BRD4ADORA2AHCRTR2HCRTR1HPGD
SCHEMBL609352 0.71 APOBEC3A (0.32) HCRTR2HCRTR1S100A4NPC1RAB9A
SCHEMBL15984819 0.70 LTA4H (0.44) BRD4ADORA2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970207-B1 SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-16 EP claimed